From yahoo mb- a very negative post but a lot of truth
—-/
Opmints don't work for a virus like Sars-Co-V-2 in VIVO.
Sales plan for buildout and Talicia rollout is kaput.
Too many chiefs and way too many Indians.
Upromissthat and cell phones is lunacy hype in a pandemic.
Aemcolo has a very narrow range of indications which don't compete well against a multitude of other drugs namely against Salix's.
Movantik is not a growth market drug, never made money and the reason it was jettisoned was because of far sighted AZ management wanted to limit any liability with opioid interactions. That market will never grow under the current circumstances.
DBA et.al. have granted themselves very lucrative option packages which they sold to insiders for cash and dilution ($1.8 million last round)
Speaking of dilution have you seen the last 3? The next round of stock has 200,000,000 shares lined up waiting to soak the market for cash and a real decline.
Ownership of ~1/3 of outstanding stock is tied to A: Cosmo B: Frank Vasile Timis. When you get done explaining the Cosmo structure of corporate ownership, get back to me with the pros. vs the cons.
It has nothing to do with pills vs. injections or topical steroids like PreparationH. It's the science no. 1. and the lack of execution in the business plan they set up 5 years ago (gastro) 2.
Take into consideration the shady ownership 3. and the ties to the low level managers in place 4. it's no wonder these continual missteps keep occurring causing them to go back into the market for more cash. 5
And the most revealing answer is the lack of transparency in all of this. Crohn's RHB-104 shelved now revisited. Talicia trumpeted now back burner. Bekinda, jettisoned. etc. They dive in with great PR, fanfare, eye popping announcements of potential and then fade away into oblivion.
An occasional patent file or regurgitation of the old press releases is now all you get.
So what's not to like! eh?
U-19
